Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered

• Main Authors: Francesca Nicolardi (Author), Federica Corona (Author), Laura Badina (Author), Irene Berti (Author), Egidio Barbi (Author)
• Format: Book
• Published: BMC, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients w...